You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed death-ligand 1

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lichen Planus Trial in Cairo (Skin Biopsy)

Not yet recruiting
  • Lichen Planus
  • Skin Biopsy
  • Cairo, Egypt
    Cairo University
May 14, 2021

Melanoma Trial (biological, drug, radiation)

Withdrawn
  • Melanoma
  • Avelumab
  • +17 more
  • (no location specified)
Mar 17, 2021

Pancreatic Cancer Trial in United States (Atezolizumab, RO7198457, mFOLFIRINOX)

Active, not recruiting
  • Pancreatic Cancer
  • Basking Ridge, New Jersey
  • +6 more
Jan 12, 2022

Programmed Cell Death 1 Trial in Assiut (Thoracic Paravertebral block)

Recruiting
  • Programmed Cell Death 1
  • Thoracic Paravertebral block
  • Assiut, Egypt
    South Egypt Cancer Institute
Dec 5, 2020

Urothelial Carcinoma Trial (biological, drug, radiation)

Withdrawn
  • Urothelial Carcinoma
  • avelumab
  • +19 more
  • (no location specified)
Mar 17, 2021

Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

Recruiting
  • Urothelial Carcinoma
  • Zilovertamab vedotin
  • Cleveland, Ohio
  • +11 more
Jan 25, 2023

NSCLC Trial (biological, drug, radiation)

Withdrawn
  • Non-small Cell Lung Cancer
  • avelumab
  • +21 more
  • (no location specified)
Mar 17, 2021

Head and Neck Squamous Cell Carcinoma Trial (biological, drug, radiation)

Withdrawn
  • Head and Neck Squamous Cell Carcinoma
  • Avelumab
  • +21 more
  • (no location specified)
Mar 17, 2021

Merkel Cell Carcinoma Trial (biological, drug, radiation)

Withdrawn
  • Merkel Cell Carcinoma
  • Avelumab
  • +14 more
  • (no location specified)
Mar 17, 2021

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Breast Tumors Trial in Israel, Korea, Republic of, United States (Atezolizumab (MPDL3280A), an engineered anti-programmed

Active, not recruiting
  • Breast Neoplasms
  • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
  • +7 more
  • Birmingham, Alabama
  • +26 more
Dec 21, 2022

Glioblastoma Multiforme Trial

Unknown status
  • Glioblastoma Multiforme
    • (no location specified)
    Feb 22, 2020

    Asymptomatic Myeloma Trial in New Haven (Atezolizumab (1200mg via IV infusion))

    Terminated
    • Asymptomatic Myeloma
    • Atezolizumab (1200mg via IV infusion)
    • New Haven, Connecticut
      Yale University
    Feb 28, 2020

    NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

    Active, not recruiting
    Has Results
    • Non-small Cell Lung Cancer
    • Pembrolizumab
    • +2 more
    • Hefei, Anhui, China
    • +16 more
    Oct 14, 2022

    Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy

    Unknown status
    • Bullous Pemphigoid
    • +2 more
    • Not concerned
    • Nantes, France
      University Hospital
    Nov 18, 2020

    NSCLC Trial in Shanghai (Injection of 99m-Tc-NM-01)

    Unknown status
    • Non-Small Cell Lung Cancer
    • Injection of 99m-Tc-NM-01
    • Shanghai, China
    • +1 more
    Aug 20, 2020

    Tumors Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a

    Completed
    • Neoplasms
    • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
    • MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
    • Scottsdale, Arizona
    • +26 more
    Mar 31, 2022

    Squamous Cell Carcinoma Trial in El Segundo (drug, biological, procedure)

    Unknown status
    • Squamous Cell Carcinoma
    • Aldoxorubicin HCl
    • +20 more
    • El Segundo, California
      Chan Soon-Shiong Institute for Medicine
    Aug 10, 2020

    NSCLC Trial in Worldwide (Sacituzumab Govitecan-hziy (SG), Docetaxel)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Anchorage, Alaska
    • +104 more
    Jul 20, 2022

    Soluble Programmed Death-1 in Predicting Progression of

    Recruiting
    • Nontuberculous Mycobacterial Lung Disease
      • Taipei, Taiwan
        National Taiwan University Hospital
      Jan 18, 2023

      Small-cell Lung Cancer, Neoadjuvant Therapy Trial in Shanghai (Atezolizumab, Carboplatin, Etoposide)

      Not yet recruiting
      • Small-cell Lung Cancer
      • Neoadjuvant Therapy
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Jan 4, 2021

      Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

      Recruiting
      • Malignant Pleural Mesothelioma, Advanced
      • Oncolytic Adenovirus H101
      • Programmed death receptor-1 inhibitor
      • Tianjin, Tianjin, China
        Tianjin Medical Unversity Second Hospital
      Sep 2, 2023

      PD-L1 Positive NSCLC Trial (Camrelizumab 200mg, Apatinib Mesylate 250mg, Pemetrexed disodium for injection)

      Not yet recruiting
      • PD-L1 Positive Non-small Cell Lung Cancer
      • Camrelizumab 200mg
      • +4 more
      • (no location specified)
      May 7, 2020

      Biliary Tract Cancer, Programmed Cell Death 1 Ligand 1 Gene Mutation, Targeted Molecular Therapy Trial in Beijing (Camrelizumab,

      Not yet recruiting
      • Biliary Tract Cancer
      • +3 more
      • Beijing, Beijing, China
        Beijing Friendship Hospital
      Jan 20, 2021

      Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

      Not yet recruiting
      • Muscle-Invasive Bladder Carcinoma
      • +2 more
      • Guangzhou, Guangdong, China
        Cancer Center, Sun Yat-sen University
      Aug 3, 2023